VXRT - Vaxart: Investment Case For An Oral COVID Vaccine Not So Hard To Swallow

• Vaxart is the oral vaccine developer with COVID, RSV, HPV, influenza and Norovirus candidates in its pipeline.
• The company faces litigation after allegedly misinforming the market about being selected for Operation Warp Speed last year.
• A COVID vaccine success is not out of the question, however - if the company can prove in a large scale Phase 2 trial, it can generate neutralising antibodies.
• Norovirus looks a possibility also, as does influenza. Results have been positive, but Vaxart needs to find a more mainstream audience.
• The novelty of an oral vaccine is surprising given the obvious benefits. Vaxart is about the only way to place a bet on its success.

For further details see: